Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Viatris (VTRS) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Treatment With 137 Μg Azelastine Hydrochloride And 50 Μg Of Fluticasone PropionateAllergic Rhinitis Due To AllergensPhase IVActive Not RecruitingDymista in Chinese AdolescentsApr 27, 2026―
Phentolamine Ophthalmic Solution 0.75%, A Non-Selective Alpha-1 And Alpha-2 Adrenergic AntagonistMesopic Vision, Night Vision LossPhase IIICompletedSafety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual DisturbancesApr 01, 2024
Mr-100A-01ContraceptionPhase IIICompletedStudy of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 CyclesOct 20, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Viatris, Inc. (VTRS) have in its pipeline
Viatris VTRS is currently developing the following drugs: Treatment With 137 Μg Azelastine Hydrochloride And 50 Μg Of Fluticasone Propionate, Phentolamine Ophthalmic Solution 0.75%, A Non-Selective Alpha-1 And Alpha-2 Adrenergic Antagonist, Mr-100A-01. These drug candidates are in various stages of clinical development as the company works toward FDA approval.